Evidence map›Paper›PMID 41085569›Full record

ReviewDiscover oncology2025

Endometrial cancer: from clinical reality to molecular treatment.

Léa-Isabelle Renaud, Elisabeth St-Laurent, Coralie Compare, Raphaëlle Proulx, Jasmine Nolan, Eric Asselin

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Léa-Isabelle RenaudDépartement de Biologie Médicale, Laboratoire de Gynéco-Oncologie Moléculaire, Université du Québec à Trois-Rivières, Trois-Rivières, Canada.
Elisabeth St-LaurentDépartement de Biologie Médicale, Laboratoire de Gynéco-Oncologie Moléculaire, Université du Québec à Trois-Rivières, Trois-Rivières, Canada.
Coralie CompareCNRS 7258, INSERM 1068, Institute Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Université Aix-Marseille, Marseille, France.
Raphaëlle ProulxDépartement de Biologie Médicale, Laboratoire de Gynéco-Oncologie Moléculaire, Université du Québec à Trois-Rivières, Trois-Rivières, Canada.
Jasmine NolanDépartement de Biologie Médicale, Laboratoire de Gynéco-Oncologie Moléculaire, Université du Québec à Trois-Rivières, Trois-Rivières, Canada.
Eric AsselinDépartement de Biologie Médicale, Laboratoire de Gynéco-Oncologie Moléculaire, Université du Québec à Trois-Rivières, Trois-Rivières, Canada. eric.asselin@uqtr.ca.

Funding

Natural Sciences and Engineering Research Council of Canada 2019-06151
6 · The paper itself

Abstract

Endometrial cancer (EC) is the most prevalent gynecological malignancy in developed countries, with incidence rates steadily increasing due to factors such as obesity, aging populations, and changes in reproductive behavior. While mortality rates have remained relatively stable, survival outcomes have improved little in recent years, underscoring the need for advancements in prevention, diagnosis, and treatment strategies. This review provides a comprehensive overview of both the clinical and fundamental aspects of EC, aiming to bridge the gap between biological research and clinical practice. On the clinical side, we assess genetic predispositions, hormonal and metabolic risk factors, classification systems, detection methods, treatment options, and their impact on survival and quality of life. From a research perspective, we highlight the models commonly used to study EC, including cell lines and animal models, and delve into the PI3K/AKT/mTOR signaling pathway, a critical driver of tumor progression and a promising therapeutic target. By synthesizing these insights, this review aims to inform future efforts to improve patient outcomes and advance the understanding of EC.

Identifiers

PMID41085569
PMCPMC12521687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.